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Abstract
CD4+ T cells orchestrate immunity against viral infections, but their importance in HIV infection remains controversial.
Nevertheless, comprehensive studies have associated increase in breadth and functional characteristics of HIV-specific CD4+
T cells with decreased viral load. A major challenge for the identification of HIV-specific CD4+ T cells targeting broadly
reactive epitopes in populations with diverse ethnic background stems from the vast genomic variation of HIV and the
diversity of the host cellular immune system. Here, we describe a novel epitope selection strategy, PopCover, that aims to
resolve this challenge, and identify a set of potential HLA class II-restricted HIV epitopes that in concert will provide optimal
viral and host coverage. Using this selection strategy, we identified 64 putative epitopes (peptides) located in the Gag, Nef,
Env, Pol and Tat protein regions of HIV. In total, 73% of the predicted peptides were found to induce HIV-specific CD4+ T cell
responses. The Gag and Nef peptides induced most responses. The vast majority of the peptides (93%) had predicted
restriction to the patient’s HLA alleles. Interestingly, the viral load in viremic patients was inversely correlated to the number
of targeted Gag peptides. In addition, the predicted Gag peptides were found to induce broader polyfunctional CD4+ T cell
responses compared to the commonly used Gag-p55 peptide pool. These results demonstrate the power of the PopCover
method for the identification of broadly recognized HLA class II-restricted epitopes. All together, selection strategies, such
as PopCover, might with success be used for the evaluation of antigen-specific CD4+ T cell responses and design of future
vaccines.
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Introduction
The cellular immune response represents a crucial component
of the battle against viral infections, including that of human
immunodeficiency virus type 1 (HIV). CD4+ T cells are critical for
maintaining and mobilising the adaptive immune response,
essentially providing helper functions to different arms of the
response. For instance, CD4+ T cells govern memory B cell
generation [1] and CD8+ T cell memory maintenance [2,3],
migration [4] and mobilisation [5] in vivo. In addition, the
borderline protection provided by the canarypox-gp120 combi-
nation in the RV144 vaccine trial [6] called further attention to
HIV-specific CD4+ T cell responses as one of few possible
correlates of vaccine protection.
CD4+ T cells direct the response against only a few of the many
potential epitopes in a process termed immunodominance.
Comprehensive analyses have shown that Gag-specific CD4+ T
cell responses dominate the total pool of HIV-specific CD4+ T
cells [7,8], and increased frequencies of these cells have been
associated with lower viral loads in HIV-infected individuals [8,9].
Many thousand different HIV strains have been characterized.
Likewise, the restricting element of the CD4+ T cell response
consists of the highly variable HLA class II molecules with more
than 2000 allelic variants known. This very high pathogen and
host diversity imposes a major challenge when it comes to
characterization of the HIV-specific CD4+ T cell responses and
identification of broadly recognized HLA class II-restricted
epitopes in populations with diverse ethnic background. To
manage these obstacles, several computational methods have been
proposed [10–13]. However, most of these methods only partially
resolve the issues raised and focus either on the pathogen or the
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HLA diversity. For instance, the Mosaic Vaccine Tool Suite [11]
constructs a mosaic protein sequence so that most viral strains are
covered ignoring the aspects of the HLA diversity. On the other
hand, the Hotspot Hunter method [12] identifies peptides with
promiscuous binding to multiple HLA molecules ignoring the HIV
genomic diversity.
We have previously identified broadly reactive HIV-specific
CD8+ T cell responses against multiple predicted HLA class I
restricted peptides in a cohort infected with various HIV subtypes
[14,15]. In the current study, we developed a novel algorithm,
PopCover, that takes into consideration both host and viral
variability to identify HIV-Gag, -Pol, -Env, -Nef and -Tat peptides
restricted to multiple HLA-DR and –DQ alleles. Combining the
PopCover algorithm with state-of-the-art HLA class II binding
prediction, we identified a small set of peptides that in concerts
provide coverage of both the viral and host genetic variations in
HIV infected patients with diverse ethnic background. Next, by
analysing the functional properties of the identified peptides, we
were able to recapitulate previous comprehensive findings such as
a correlation of viral load to the breadth and polyfunctionality of
the HIV-peptide-specific CD4+ T cell responses.
Results
To enable the identification of broadly reactive HLA class II-
restricted peptides, and the patterns of immunodominance and
functionality, a diverse patient cohort infected with multiple viral
subtypes was identified. The study cohort consisted of 38 HIV-
infected individuals infected with ten different HIV-1 subtypes
(Table 1). In total, 13 subjects were untreated, and 25 subjects
were on treatment. One treated patient had low-grade viremia due
to poor treatment adherence. High-resolution HLA-typing for the
HLA class I and II genes of 37 patients confirmed that the cohort
was highly genetically diverse (data not shown).
Prediction of Broadly Reactive HLA Class II-restricted HIV
Peptides
A set of full-length HIV proteomes were scanned using
NetMHCII [16] and NetMHCIIpan [17,18] to identify 15-mer
peptides within Gag, Pol, Env, Nef, and Tat that were predicted to
bind one or more of 45 prevalent HLA class II alleles. From the
pool of more than 225,000 predicted binders, a final set of 64
peptides (15 Gag, 15 Pol, 15 Env, 15 Nef, and 4 Tat) was selected
using the PopCover algorithm to ensure broad coverage of both the
prevalent HLA class II alleles and the major HIV subtypes (see
Materials and Methods for details). The power of the PopCover
selection algorithm can be illustrated from the peptide selection
within the Nef protein dataset (Figure 1). This dataset consists of
20,962 unique 15-mer peptides with predicted binding to one or
more of the 45 HLA class II alleles. The 15 selected Nef peptides
target 43 of the 45 HLA alleles (95%) and 392 of the 396 HIV
genomes (99%). Using a selecting strategy in which only the allelic
frequency is included in the scoring function (i.e., ignoring Eik in
the scoring function for peptide selection and solely focusing on
peptide conservation), these values are reduced to 60% and 92%,
respectively. The high coverage of the HLA alleles as a function of
peptide selection demonstrates that the PopCover selection strategy
ensures a broad coverage of the 45 HLA class II alleles. Not one
single peptide achieves an HLA coverage beyond 68% (31 alleles)
and an HIV genomic coverage beyond 64% (253 strains). Only
when taken as a group complementing the individual peptide-
characteristics does the peptide-selection reach the high coverage
values. The same principle, as described above for Nef, was used
for the other HIV protein regions to select high-scoring peptides
that generate broadly reactive HIV-specific CD4+ T cell
responses. The exact number of peptides included from each
HIV region (15 from Gag, Pol, Env, and Nef and 4 from Tat) was
chosen to ensure a reasonably homogeneous sampling of the
relevant proteomic regions reflecting the protein size and
importance for the study.
The overall characteristics of the five peptide-pools in terms of
predicted binding properties, HLA restrictions, and the number of
targeted HIV strains are given in Table 2. The high genomic
diversity of HIV and the variation between the different HIV
proteins are quantified in the table. The Env protein, for instance,
has the largest number of unique predicted peptide binders.
Taking into account the different data set sizes and calculating the
number of unique binders per amino acid in each data set, the Env
data set has on average 0.346 unique predicted binding peptides
per amino acid. The numbers in Table 2 hence confirm that
among the five HIV proteins, Env is the most variable followed by
Nef, and Pol being the most conserved.
Table 3 demonstrates that all peptide pools, with the exception
of the Tat pool, have very similar properties in terms of predicted
HLA binding, and the coverage of HLA molecules and viral
strains. Due to the relative high sequence conservation of the Pol
proteins, the individual Pol peptides targets a higher fraction of the
HIV strains than peptides from the other pools. Likewise, as a
result of the high sequence variation of the Nef protein data set
and the short length of the Nef protein region, the average fraction
of HIV strains targeted by the Nef peptide pool is relatively low.
Immunodominance of Broadly Reactive HLA Class II-
restricted Gag and Nef Peptides
Peptide-specific T cell responses were first identified by the
IFNc ELISPOT assay using freshly isolated PBMCs. By dividing
the peptides into different pools (Table S1), spot forming units
(SFU) were distinguished to identify the responses in a first line
screening process. Individual peptide-specific CD4+ T cell
responses were subsequently identified using functional flow
cytometric analysis to detect the production of IFNc, IL-2, IL-
21, MIP-1b and TNF. Out of the 64 peptides, 47 (73%) generated
a CD4+ T cell response in at least one patient. There was a clear
skewing of CD4+ T cell responses toward Gag and Nef peptides
(Figure 2A). The percentage and number of individuals recognis-
ing each peptide is stated in Table S1. Each subject recognised a
median of 5 peptides (IQR: 2.75–6.00) with a maximum of 12
recognised peptides, which was observed in one patient (Figure 2B).
Within the cohort, almost all of the peptides derived from the Gag
(100%) and Nef (93%) regions and the majority of the peptides
from the Pol (66%) and Tat (75%) regions were immunogenic,
while only a limited number of peptides located in the Env (33%)
region generated responses (Figure 2C).
Although a majority of peptides within the different HIV
protein regions were recognised, the fraction of tested peptides in
each region that elicited responses differed (one-way ANOVA:
P,0.001, n = 38; Figure 2D). Gag and Nef peptides were more
broadly reactive and induced responses in a significantly higher
fraction of individuals than did peptides in other protein regions.
Gag- and Nef-specific CD4+ T cell responses were detected at
least 4.4 (P,0.001, n = 38) and 2.5 (P,0.01, n = 38) times more
frequently than responses against the Pol, Env, and Tat peptides
(Figure 2D). There were no statistically significant differences in
the frequencies of the responses between peptides in the Pol, Env,
and Tat regions. The distribution of the responses is illustrated in
Figure S1. Interestingly, a significant inverse correlation was
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observed between the number of targeted Nef and Gag peptides (r
= 20.36, P = 0.029, exact permutation test, n = 38), implicating
that CD4+ T cell responses in the majority of the cohort were
dominated by either broad Gag- or Nef-specific responses.
HLA Restriction for Peptides Inducing CD4+ T Cell
Responses using Prediction Tools
Binding to one or more of the donors HLA molecules is a
prerequisite for a peptide to induce a T cell response. An HLA
restriction analysis was performed for the observed CD4+ T cell
responses. The analysis was limited to the subset of alleles where
Table 1. Clinical data of study cohort.
ID Age Ethnicity Sex CD4+count Nadir CD4+ Viral load Subtype1 Treatment2
THS-1 51 Caucasian Male 477 120 ,50 B 3TC, ABC, ATV, RAL
THS-2 48 Caucasian Male 768 190 ,50 B EFV, FTC, TDF
THS-3 50 Caucasian Female 790 120 ,50 B 3TC, ABC, NVP
THS-4 51 Caucasian Male 636 300 ,50 B ETR, RAL
THS-5 52 Caucasian Male 1495 280 ,50 CRF01_AE EFV, FTC, TDF, RAL
THS-6 51 Latin Female 576 190 ,50 A2 EFV, FTC, TDF
THS-7 59 Caucasian Male 438 354 ,50 CRF01_AE 3TC, ABC, ATV, RTV
THS-8 64 Caucasian Male 602 273 ,50 B 3TC, ABC, EFV
THS-9 44 Caucasian Male 740 204 ,50 CRF01_AE 3TC, ABC, ATV
THS-10 46 Caucasian Male 500 31 ,50 B EFV, FTC, TDF
THS-11 48 Caucasian Male 853 576 ,50 B EFV, FTC, TDF
THS-12 48 Caucasian Male 685 216 ,50 C ATV, FTC, RTV, TDF
THS-13 52 Caucasian Male 1076 444 ,50 B 3TC, ABC, ATV
THS-14 34 Caucasian Male 822 206 ,50 B 3TC, ABC, ATV
THS-15 33 African Female 660 145 227 A1,G 3TC, TDF, AZT
THS-16 65 Caucasian Male 686 260 ,50 B 3TC, ABC, ATV
THS-17 40 Caucasian Male 625 10 ,50 ND3 3TC, ABC, LPV, RAL, RTV
THS-18 54 Caucasian Male 1010 393 ,50 B 3TC, ABC, EFV
THS-19 46 Caucasian Male 646 367 ,50 B ABC, 3TC, RAL
THS-20 47 Caucasian Male 900 300 ,50 B 3TC, ABC, ATV
THS-21 56 Caucasian Male 446 284 ,50 B EFV, FTC, TDF
THS-22 47 Caucasian Male 440 390 ,50 B EFV, FTC, TDF
THS-23 40 Caucasian Female 364 258 ,50 CRF01_AE EFV, FTC, TDF
THS-24 41 Caucasian Male 724 170 ,50 B FTC, LPV, RTV, TDF
THS-25 38 Caucasian Male 780 50 ,50 B 3TC, ABC, ATV, RTV
THS-26 37 African Female 670 447 485 CRF21_A2D Naive4
THS-27 44 Caucasian Female 600 307 60500 CRF02_AG Naive
THS-28 30 Caucasian Female 560 418 2640 CRF03_AB No treatment5
THS-29 62 Caucasian Male 480 480 27500 CRF01_AE Naive
THS-30 53 Caucasian Male 310 310 10100 CRF03_AB Naive
THS-31 57 Caucasian Male 475 378 8790 B Naive
THS-32 35 Caucasian Male 522 389 37600 B Naive
THS-33 43 Caucasian Male 481 403 40500 B Naive
THS-34 22 Caucasian Male 534 407 7140 B Naive
THS-35 24 Latin Male 460 359 128000 G Naive
THS-36 45 African Female 480 400 17800 A1 Naive4
THS-37 44 Caucasian Male 593 593 26900 B Naive
THS-38 30 Caucasian Male 410 400 45000 B Naive
1The HIV subtypes were obtained through sequence analysis of HIV gag (p17 and p24).
23TC, lamivudine; ABC, abacavir; ATV, atazanavir; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; NVP, nevirapine; LPV, lopinavir; RAL, raltegravir; RTV, ritonavir; TDF,
tenofovir.
3Not determined.
4Female who has received AZT during delivery.
5Received antiretroviral treatment for only five month, more than a year prior to sample collection.
doi:10.1371/journal.pone.0039874.t001
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accurate prediction methods exist (HLA-DR covered by NetMH-
CIIpan-2.0, and 5 DP and 6 DQ alleles covered by NetMHCII-2.2).
Using a binding threshold of 500 nM, we found that 160 of the
172 (93%) positive CD4+ T cell responses in donors with known
HLA type could be explained by predicted binding to one or more
of the donor HLA class II molecules. Several of the epitopes were
predicted to be highly promiscuous and the median number of
predicted restriction elements per peptide was 5. The highest
number of restrictions (40) was found for the peptide
VDRFYKTLRAEQASQ earlier reported to have a high cross-
reactive binding capacity [7]. Likewise, were the HLA-
DRB1*0101 and HLA-DRB1*1501 molecules found to be the
most prevalent restriction elements predicted to bind 31 and 32,
respectively, of the 46 experimentally validated epitopes in donor
with annotated HLA types. Details on the number of distinct
predicted HLA restrictions for each positive peptide is included in
supplementary table S1.
Inverse Correlation between the Breadth of Gag-specific
CD4+ T Cell Responses and Viral Load
Next, clinical parameters were associated with the breadth of
peptide-specific CD4+ T cell responses. Figure 3 gives the result of
such an analysis and demonstrates that broad Gag targeting is
significantly and inversely correlated with viral load in viremic
individuals (r = 20.619, P = 0.018, n = 14). The correlation was
not maintained when looking at recognised peptides from all of the
HIV protein regions (data not shown). No correlations between
broad peptide targeting and CD4+ T cell counts were identified.
Functional Discrepancies between CD4+ T Cells
Targeting Different HIV Proteins
While Gag and Nef peptides induced CD4+ T cell responses
more frequently than the Pol, Env and Tat peptides, the
magnitudes of the detected responses were not significantly
different (one-way ANOVA: P.0.05, n = 38; data not shown).
Figure 1. Selection of Nef-specific epitopes using the PopCover algorithm. Fifteen Tat 15-mer peptides were selected from the pool of
20,962 predicted HLA class II binders. Each row in the figure represents one peptide, and each column represents an HLA class II molecule. The value
in each cell gives the cumulative number of times a given allele was predicted to bind any of the selected peptides. The first selected peptide covered
only 11 over the 45 HLA alleles, however, when combined with the other peptides in the pool, the HLA coverage increased to 96% (43 out of 45).
When taking the allelic frequency into account, this corresponded to a population-coverage of 99.8%. The coverage of the HIV genomes was similar.
The first selected peptide (FPVRPQVPLRPMTYR) is present in 253 of the 396 genomes (64%) included in the analysis. With the other peptides in the
pool, this coverage is increased to 99.0%.
doi:10.1371/journal.pone.0039874.g001
Table 2. Characteristics of peptides and peptide-pools for the five HIV protein regions.
Protein
Unique predicted
binders Strains Protein length Unique/(length*strain)
Gag 31,848 396 498 0.161
Pol 42,749 396 1,003 0.108
Env 125,926 424 859 0.346
Nef 20,962 396 204 0.259
Tat 5,608 395 101 0.141
The column ‘‘Unique predicted binders’’ gives the number of unique 15mer peptides in each genomic data set predicted to bind one or more of the 45 HLA class II
molecule. Unique/(length*strain) gives the number of unique binders divided with the total number of amino acids in the given genomic data set (protein length *
number of strains).
doi:10.1371/journal.pone.0039874.t002
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The median magnitude (% of tot CD4+ T cells) and IQRs of the
responses against each peptide is depicted in Table S1. The similar
magnitudes of the responses of HIV-specific CD4+ T cells
targeting the predicted peptides from the diverse protein regions
allowed us to study functional discrepancies between the different
HIV proteins. A boolean gating principle was applied to create
combinational events of IFNc, IL-2, IL-21, MIP-1b and TNF in
order to investigate functional diversities (Figure 4A). By measur-
ing the diversity of polyfunctionality, we found that immunogenic
Nef peptides (n = 56) led to the production of more functional
combinations of these cytokines than did the immunogenic Gag (P
= 0.006, n = 99), and Pol (P = 0.033, n = 15) peptides (Figure 4B).
In addition, the immunogenic Gag peptides induced a more
functionally diverse response compared to the set of overlapping
pool of Gag-p55 peptides (P = 0.035) that was used as one of the
positive controls (Figure 4B). More precisely, the CD4+ T cells
that targeted the predicted Nef and Gag epitopes expressed three
functional combinations more frequently than cells recognising the
overlapping Gag-p55 peptide pool. The Gag-p55 peptide pool-
specific CD4+ T cells frequently exhibited monofunctional
responses, particularly TNF and, more modestly, MIP-1b
(Figure 4C). There were no significant functional differences
observed for the positive Env and Tat peptides when compared to
the other protein regions, probably due to the lower number of
responses. Taken together, these data suggests that the HLA class
II restricted peptides identified in this study generate an improved
polyfunctionality compared to overlapping peptides.
Discussion
The tremendous variability of the human immune system and
the HIV genome represents a major challenge in identifying
broadly reactive, peptide-specific CD4+ T cell responses in diverse
populations. The utilisation of bioinformatics to identify T cell
responses to HIV infections has increased in the last few years
[14,19,20]. For peptide prediction, the in silico prediction methods
NetMHCIIpan and NetMHCII developed to predict HLA class II
restricted peptide binding have proven to be among the best
methods available [21]. Here, we integrated these prediction
methods with a novel algorithm, PopCover, to select HLA-DR- and
–DQ-restricted HIV peptides with broad HLA allelic and HIV
genomic coverage. PopCover integrates HLA binding predictions
with information about HLA allelic prevalence in a given
population and selects pools of peptides that, in concert, will
provide broad coverage of both the pathogen genome (i.e. HIV
subtypes and strains) and HLA diversity. Using this approach, 64
top-scoring peptides were selected to identify broadly reactive
HIV-specific CD4+ T cell responses. A majority of the predicted
peptides were found to be immunogenic. The Gag- and Nef-
specific CD4+ T cell responses dominated. Targeting of Gag
peptides was found to be associated with a lower viral load in
viremic individuals. Importantly, a vast majority of the peptides
were predicted to be restricted to one or more of the donor’s HLA
class II alleles.
At least one of the predicted HLA class II binding peptides
generated a response in 37 out of 38 individuals. Freshly isolated
PBMCs were used to assay the peptide immunogenicity as it has
been demonstrated to the increase the detection sensitivity of HIV-
specific CD4+ T cell responses [22]. In total 47 (73%) of the
predicted peptides generated a CD4+ T cell response. Although a
majority of the peptides were immunogenic, CD4+ T cell
responses against Gag and Nef occurred more frequently, which
recapitulates other comprehensive studies [7,8]. Previously,
through a comprehensive analysis that used 410 overlapping
peptides spanning the entire HIV subtype B genome, Kaufmann et
al. [7] detected eight peptides (1.8%) that were recognised in more
than 25% of the study cohort (n = 36). Using only 64 peptides, we
identified eight immunodominant peptides (12.5%) that generated
CD4+ T cell responses in at least 20% of our subjects. Similarly,
when the frequencies of peptide-specific responses per patient are
compared between the studies, our approach was 4.4-times more
likely to identify peptide-specific responses. Kaufmann et al.
detected responses against 1.7% of the tested epitopes (range 0–
8.3%), while our approach detected 7.5% (range 0–17%).
Most of the peptides described as immunodominant in the
present study have been described previously. For example, the
most immunogenic of our predicted peptides (VDRFYKTLRAE-
QASQ – Gag-VQ15) is located within a conserved part of the
Gag-p24 region important for capsid oligomerization [23]. Gag-
VQ15 has been identified as the most frequently targeted peptide
by CD4+ T cells in subtype B infected subjects [7] potentially due
to its restriction to multiple HLA-DR alleles (http://www.hiv.lanl.
gov/). The second most immunogenic peptide, EVLMWKFDSR-
LAFHH – Nef-EH15, overlapped with another peptide sequence
(10 amino acids), previously shown to bind to a diverse set of HLA-
DRB1 and HLA-DRB5 alleles (http://www.hiv.lanl.gov/). How-
ever, other immunodominant peptides that generated responses in
.20% of our study subjects, (e.g. Nef-FR15 and Gag-GL15) have
not been described previously as broadly immunogenic peptides.
Out of 47 peptides generating CD4+ T cell responses, only 75%
(35) shared a 9 mer core (9 consecutive identical amino acids) with
one or more known HLA class II-restricted epitopes from the Los
Alamos HIV database. According to this criteria, 25% of the
peptides generating responses are thus of novel character.
Despite the fact that HIV preferentially infects HIV-specific
CD4+ T cells [24], early preservation of these cells most probably
represent a crucial mechanism for viral control [25,26]. Specific
targeting of the Gag peptides by CD4+ T cells has been associated
with lower viremia in both adults [27] and children [28,29]. A
Table 3. Characteristics of peptides and peptide-pools for the five HIV protein regions.
Per pool Average per peptide
Protein Pool size Fraction of HLAs hitFraction of strains hit 1-log50 k Fraction strains hit Fraction of HLAs hit
Gag 15 0.978 0.997 0.590 0.674 0.578
Pol 15 1.000 1.000 0.547 0.891 0.511
Env 15 0.978 1.000 0.556 0.531 0.578
Nef 15 0.956 0.990 0.545 0.235 0.378
Tat 4 0.667 0.775 0.515 0.258 0.356
doi:10.1371/journal.pone.0039874.t003
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Figure 2. Immunodominance of predicted Gag- and Nef-specific CD4+ T cell responses. (A) Overall immunogenic analysis illustrating the
individual peptides that generated a CD4+ T cell response. The vertical axis represents the total number of individuals that recognised each peptide,
while the horizontal axis illustrates the individual peptide numbers within each HIV region. (B) Distribution of the number of recognised peptides per
individual. (C) Percentage of peptides from different HIV proteins that induced a CD4+ T cell response. (D) Fraction of tested peptides from different
HIV protein regions that generated CD4+ T cell responses per individual. The statistical analysis was performed with a one-way ANOVA and a non-
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recent study has demonstrated an inverse correlation between viral
load and the number of Gag peptides targeted by CD4+ T cells
[9]. Our data in viremic subjects confirm this finding, suggesting
that broadly reactive Gag-specific CD4+ T cell responses could
have an impact on HIV disease progression. However, whether
the frequent targeting of Gag peptides is the cause or the
consequence of the reduced viremia remains to be clarified.
The functional characteristics of HIV-specific T cells have been
proposed to correlate to the viremic state of the individual [30–
33]. In our cohort, we found differences in the polyfunctionality of
the CD4+ T cells targeting the different HIV protein regions. Of
note, it was demonstrated that the CD4+ T cell responses induced
by the overlapping Gag-p55 peptide pool were skewed toward a
more limited functional profile compared to the predicted, broadly
reactive Gag and Nef peptides. These variations should be
considered when interpreting HIV-specific CD4+ T cell responses.
Additionally, the Nef-specific CD4+ T cell responses showed the
highest degree of polyfunctionality. However, this might have been
linked to the tendency of increased Nef targeting within the treated
individuals (unpublished observations).
In summary, we believe to have demonstrated that computa-
tional predictions in general provide a powerful tool for studying
peptide-targeting in natural infection and vaccine trials. Particu-
larly, we have shown that the PopCover method is a simple yet
highly effective method for selection of peptide-pools covering
both pathogen and host immune system diversity. In the present
study, it was shown that 64 predicted HLA class II-binding
peptides could be used to reveal a pattern of CD4+ T cell
immunodominance similar to that yielded by comprehensive
analysis spanning the entire HIV genome. In addition, both the
functional properties and breadth of specific CD4+ T cell
responses in correlation with viremia revealed patterns similar to
previous comprehensive studies. In conclusion, the utilization of
peptide selection strategies, like PopCover, might be fruitful in the
future design and evaluation of HIV vaccines.
Materials and Methods
Ethics Statement
This study was approved by the Regional Ethical Council
(Stockholm, Sweden 2009/1592-32) and all study participants
provided informed consent. Oral and written information was
provided. Oral informed consent was documented in the patients’
journal. Written informed consent was not provided as HIV
infected individuals, especially from non-literate and developing
societies, may view the use of written consent documents as a
binding document, not protecting the study participant. This
perception can undermine trust and may risk coercing people to
sign such documents.
Subjects
A total of 38 HIV infected individuals were recruited from the
Karolinska University Hospital and Stockholm South General
Hospital, Stockholm, Sweden (Table 1). Patient inclusion was
based on the single criteria of a CD4+ T cell count .300 cells/
mm3 to ensure detection of HIV-specific CD4+ T cell responses.
Of the included patients, 25 were treated (viral load ,50 copies/
mL, except for individual THS-15) and 13 untreated (viral load
.50 copies/mL).
Prediction and Selection of Peptides
The peptide selection was made from a dataset containing
between 395 and 424 (depending on the given HIV protein) full-
length HIV genomic sequences covering 50 subtype A, 104
subtype B, 156 subtype C, 40 subtype D and 46 CRF_01AE
strains. For each HIV amino acid sequence the HLA peptide
binding prediction methods NetMHCII [16] and NetMHCIIpan
[17,18] were applied to predict 15 mer peptide-binders to a set of
HLA class II alleles. Four prevalent HLA-DQ alleles
(DQA1*0101-DQB1*0501, DQA1*0301-DQB1*0302,
DQA1*0401-DQB1*0402, and DQA1*0501-DQB1*0301),
38 HLA-DRB1 alleles and HLA-DRB3*01:01, HLA-
DRB4*01:01 and HLA-DRB5*01:01 were included in the
analysis. A predicted IC50 value of 500 nM was applied to define
peptide-binders. Next, peptides were selected using a novel
algorithm, PopCover, to maximize broad allelic and pathogen
coverage. The scoring function used to select peptides was defined
as
SAzGj ~
X
i
X
k
R
j
ki
:fk:gi
bzEik
where Rjki is 1 if peptide j is present in genome i and is presented by
allele k, Eik is the number of times allele k has been a target by
peptide in genome i by the already selected set of epitopes, gi is the
genomes frequency which is normally set to being uniform, fk is the
allelic frequency of allele k, and b is a tuneable constant set to
penalize un-targeted pathogen-HLA pairs. The scoring function is
iteratively applied to all predicted peptide binders from the
pathogen proteomes/protein to the alleles included in the study,
and the highest scoring peptide is selected in each selection round.
In total, the number of unique predicted 15 mer HLA class II
binders for each protein set was 125,926 (Env), 31,848 (Gag),
20,962 (Nef), 42,749 (Pol), and 5,608 (Tat). From this set of
predicted peptides, the PopCover algorithm, using a value of b
parametric Kruskal Wallis test with Dunn’s multiple comparison test to compare all of the pairs of columns; *P,0.05, **P,0.01 and ***P,0.001. The
data are derived from 38 independent experiments (mean and SEM).
doi:10.1371/journal.pone.0039874.g002
Figure 3. Association between the breadth of Gag-specific
CD4+ T cells and HIV viremia. Correlation between CD4+ T cells
targeting multiple Gag peptides and viral load in viremic subjects using
the Spearman non-parametric test. Similar correlation and significance
was obtained excluding subject THS-15, who had low-grade viremia
and documented poor treatment adherence.
doi:10.1371/journal.pone.0039874.g003
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=0.05, was applied to select the final set of 64 (15 Gag, 15 Pol,
15 Env, 15 Nef, and 4 Tat) top-scoring peptides. When the
PopCover algorithm is initialized, the variable Eik in the PopCover
scoring function is zero for all alleles and genomes, and the first
peptide selected is the peptide that is present in most HIV
genomes and binds to the set of HLA alleles with the highest allelic
frequency sum. When the next peptide is selected, the score for
targeting an allele and genome already covered by the first peptide
is lowered by a factor (1+ b)/b =21 (ignoring differences in allelic
frequency and assuming equal genomic coverage) and the
selection will hence focus on identifying peptides that target
previously un-targeted HLA alleles and genomes.
HIV Extraction, Sequencing and Subtyping
RNA or DNA was extracted from plasma or PBMCs using the
RNeasy Lipid Tissue Mini Kit or DNA kit (Qiagen). The RNA
was used to generate cDNA, whereas the DNA was directly used
for PCR. A nested PCR for the HIV gag gene (p17 and p24) was
performed as previously described [14,34] with some primer
modification.
Sequencing was performed using the BigDye Terminator
Version 3.1 Cycle Sequencing Kit (Applied Biosystems) and
detected in the ABI PRISM 3130xl Genetic Analyzer (Applied
Biosystems). Sequences were imported and manually edited using
Sequencher software (Gene Codes). The gag gene sequences and
recommended subtype reference sequences (www.hiv.lanl.gov)
were used to construct neighbour-joining phylogenetic trees using
the MEGA 4 software [35]. Phylogenetic tree analysis was used to
determine the subtype of the gag gene sequence and to facilitate
detection of possible PCR contamination and sample mix-up.
Subtyping results were also compared with online subtyping by
Standford and REGA tools. The HIV gag sequences have been
submitted to GenBank and given the accession numbers
JQ229725 - JQ229761.
Figure 4. Functional discrepancies of CD4+ T cells targeting predicted peptides of different HIV protein regions. (A) Representative
flow cytometric plots showing the pattern of CD4+ T cell TNF secretion along with IFNc, IL-2, MIP-1b and IL-21 upon Gag-p55 stimulation. (B) Pie
charts representing the fraction of functions upregulated by the various HIV protein-specific CD4+ T cells; from one (yellow) up to five functions
(black) are illustrated by the colour-scale. Permutation tests were performed to compare the differences between the pie charts. (C) Frequency
comparison of the functions of Nef-specific (blue), Gag-specific (red) and Gag-p55-specific (orange) CD4+ T cells for each of the 31 functional
combinations. Bars represent the means of a functional combination, and upper whiskers show SEM. Significant differences between the bars for
Gag-p55 and Gag or Nef are represented by +, which indicates P,0.05 using Student’s t-test.
doi:10.1371/journal.pone.0039874.g004
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HLA Typing
HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, and -DRB
genes were amplified by PCR from patient DNA samples, using
gene specific primers for each HLA gene. PCR amplification was
performed according to Luo et al. [36], using Taq DNA
polymerase (Invitrogen). PCR products were examined by agarose
gel electrophoresis and purified using the Agencourt AMPure
PCR magnetic bead purification system (Beckman Coulter). The
purified PCR products were sequenced using an ABI PRISM
BigDye Terminator Cycle sequencing system (Applied Biosystems)
and analyzed with an ABI Prism 3130 or 3700 Genetic Analyzer
(Applied Biosystems). HLA genotyping was performed using
computer software based on a Taxonomy-Based Sequence
Analysis method [36,37].
Peptides
The synthesized peptides (n = 64) were all 15-mers with purity
greater than 70% (Genscript). All peptides were used at a final
concentration of 2 mg/mL. As positive controls, peptide pools
consisting of HCMV pp65 and HIV Gag-p55 (15-mers overlap-
ping by 11 amino acids) (JPT technologies) and Staphylococcal
enterotoxin B (SEB) (Sigma Aldrich) were obtained with .70%
purity. Overlapping peptides were added to a final concentration
of 1 mg/mL whereas SEB was used at a final concentration of
2.5 mg/mL.
ELISPOT
Fresh PBMCs were isolated from whole blood collected in
heparin tubes by Hypaque-Ficoll (GE Healthcare) gradient
centrifugation and washed in RPMI 1640 Glutamax (Invitrogen),
supplemented with 10% FCS (Invitrogen), 50 IU/mL penicillin
and 50 mg/mL streptomycin, and 10 mM HEPES (R10). The
IFNc ELISPOT has been described elsewhere [14].
Conjugated Antibodies
The following directly conjugated antibodies were used to detect
antigen-specific T cell responses: CD3–APC-H7 (SK7), CD4–
V450 (RPA-T4), CD8–Amcyan (SK1), IFNc–FITC (B27), TNF–
PE-Cy7 (MAb11), IL-2–APC (MQ1-17H12), MIP-Ib–PerCP-
Cy5.5 (D21-1351) and IL-21–PE (3A3-N2.1) (BD Biosciences).
Intracellular Cytokine Staining (ICS)
Directly following the ELISPOT analysis each single predicted
peptide, from the peptide pools generating responses in the
ELISPOT experiments, were tested individually using ICS [38].
Fresh PBMC counts and viability were assessed using a
Nucleocounter (ChemoMetec A/S) and resuspended in R10 to a
concentration of 56106 cells/mL. U-bottom plates were plated
with predicted peptides, positive controls (p55, CMV and SEB) or
medium alone (negative controls) together with 56105 PBMCs/
well. Brefeldin A (Sigma Aldrich) was supplemented (5 mg/mL)
after 1 hr to each well and further incubated at 37uC for 11–
13 hrs.
The following day, cells were transferred to V-bottom plates,
washed and stained with CD8 for 20 min at 4uC. Cytofix and
Perm2 (BD Biosciences) were added to fix and permeabilize the
cells. After further washing, intracellular staining with CD3, CD4,
IFNc, TNF, IL-2, MIP-Ib and IL-21 was performed for 20 min at
24uC. Cells were washed and resuspended in PBS containing 1%
paraformaldehyde PFA. All flow cytometric analyses were
conducted within 5 hrs.
Flow Cytometric Analyses
PBMCs were analysed on a standardized 8 colour CantoII (BD
Biosciences) where minimally 150.000 total events were collected
(typically around 250.000 total events) per run. Data compensa-
tion was performed using antibody capture beads (BD Biosciences)
separately stained with each single antibody used in the panel.
Flow cytometric gating analyses was performed using FlowJo 8.6.6
(Treestar). Representative flow cytometric plots demonstrate the
gating procedure in Figure S2A and the subsequent CD4+ T cell
gating for detection of two different peptide-specific responses
(Figure S2B). For all patients, two negative controls were used.
Based on two negative controls, we used two criterions to define
a positive response, where either needed to be fulfilled, First, the
peptide-specific CD4+ T cell responses were considered positive if
the frequency of responding cells was twice the average negative
background and over 0.02% of all CD4+ T cells for a single
cytokine. Secondly, to increase detection sensitivity in borderline
cases or when background was high, we used an additional
criterion to distinguish positive responses by plotting different
cytokines on the x- and y-axis [39]. If the frequency of double
positive cells for any cytokine combination was four times higher
than the average negative background, a response was considered
positive.
Statistics
Experimental variables between two groups of individuals were
analyzed using Mann-Whitney U test and Wilcoxon matched-
pairs rank test. One-Way ANOVAs followed by Kruskal-Wallis
non-parametric Dunn’s multiple comparison tests were used to
analyze three groups or more. Correlations were assessed using
non-parametric Spearman rank tests. Statistical analyses were
performed using GraphPad Prism 5.0 (GraphPad Software). All
pie charts were analyzed by permutation tests using the data
analysis program SPICE version 5.2009, provided by Mario
Roederer, VRC, NIAID, NIH [40].
Supporting Information
Figure S1 Distribution of peptide targeting within
different HIV protein regions. Scatter plots showing the
fraction of tested peptides within different HIV protein regions
that generated CD4+ T cell responses per individual (median and
IQR).
(TIF)
Figure S2 Gating principle to distinguish HIV-specific T
cell responses. (A) Flow cytometric plots illustrating the gating
strategy used to distinguish a pure CD4+ and CD8+ T cell
population. The plots are for patient THS-31 (B) the negative
control (left plots) and two Gag-specific CD4+ T cell responses
against peptides FSPEVIPMFSALSEG – Gag-FG15 (middle plots)
and RWIILGLNKIVRMYS – Gag-RS15 (right plots). The
threshold for a CD4+ T cell responses was set to be twice the
negative background for any cytokine and .0.02% of the total
CD4+ T cell frequency. As illustrated in the top right plot, Gag-
RS15 generated a positive CD4+ T cell response well over the
threshold while Gag-FG15 induced a response just below
borderline for TNF. To distinguish whether there was an actual
response against Gag-FG15, TNF versus IL-2 plots were
constructed (bottom rows). The quadrant gating shows that
TNF+IL-2+ cells were over nine times the frequency of the
negative control. This was more than four times the cut off (second
criteria) and was thus interpreted as a positive response.
(TIFF)
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Table S1 Peptide sequences and percentages of re-
sponses. Detailed information on the peptides sequences, pool
configuration, and measured T cell response.
(PDF)
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